« Pfizer Bid Sees Shadow. Now 6 Months Wait for AZ Takeover. | Main | AZ Shareholder Suggests Management Put Up or Shut Up »

05/21/2014

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Bruce M. Lehr

More on this today (5/30) from PharmaTimes quoting the President of PhRMA on insurer's short-sightedness in criticizing Sovaldi on price alone
http://www.pharmatimes.com/Article/14-05-29/PhRMA_chief_tears_into_insurers_over_Sovaldi_cost_moans.aspx

Bruce M. Lehr

More commentary on this by Derek Lowe and John LaMattina in In the Pipeline (5/29)
http://pipeline.corante.com/archives/2014/05/29/the_price_of_sovaldi.php

Sunkcosts

Couldn't agree more. Yes, Gilead is making a killing on it, but if you look at all the costs associated with an HCV infected population, the downstream benefits to our healthcare system by curing these people now rather than letting their disease progress are immense.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada